PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

An anticancer drug opens a new path for the treatment of Parkinson's

The metabolic product of an anticancer drug demonstrates potential activity in neurons derived from Parkinson's patients and a synergistic action, together with the original drug, in prostate cancer cells

2024-02-09
(Press-News.org)

L'Hospitalet de Llobregat, February 8th, 2024. Once they enter the body, drugs, apart from carrying out their therapeutic function, are biochemically transformed by the action of the metabolic machinery, a process that facilitates their expulsion. This biotransformation results in a gradual disappearance of the drug, which is converted into its metabolites. These, in turn, can reach high concentrations in the body and also show a biological activity that may be different from that of the original drug. That is, the metabolites and the drug coexist in the body, and can cause effects different from those obtained with the individual molecules. This is the case of Rucaparib, a drug used in chemotherapy for ovarian cancer, breast cancer and, more recently, prostate cancer, and its metabolite, the M324 molecule. Rucaparib is part of a group of drugs designed to treat several types of cancers that show alterations in DNA repair. Specifically, they are inhibitors of the PARP1 enzyme, involved precisely in the process of repairing mutations in the genetic material.

A study led by researchers Albert A. Antolin, from the Oncobell program of the Bellvitge Biomedical Research Institute (IDIBELL) and ProCure of the Catalan Institute of Oncology (ICO), and Amadeu Llebaria, from the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC ), has shown that Rucaparib and its main metabolite M324 exhibit differential activities. Published in the journal Cell Chemical Biology, the paper has analyzed Rucaparib and M324, making a computational prediction of the metabolite's activity. The article describes the synthesis of M324 and its biological assay, demonstrating that the drug and its metabolite have differentiated activities and act synergistically in some prostate cancer cell lines. And that, surprisingly, M324 reduces the accumulation of the protein α-synuclein (an important component of Lewy bodies) in neurons derived from patients with Parkinson's, a neurodegenerative disease characterized by a movement disorder, and in which neurons do not produce sufficient amounts of the neurotransmitter dopamine.

Specifically, the synergy demonstrated between Rucaparib and M324 in prostate cancer cell lines could have an impact on clinical trials for advanced stages of this type of cancer. On the other hand, the fact that M324 is capable of reducing the abnormal accumulation of α-synuclein in neurons derived from stem cells of a Parkinson's patient, highlights the therapeutic potential of this metabolite and its possible pharmacological application for the treatment of this neurodegenerative disease. These results have been obtained thanks to the collaboration of the IDIBELL and ICO groups led by Miquel Àngel Pujana and Álvaro Aytés, and the group of Antonella Consiglio, from IDIBELL and the UB.

Researchers have used computational and experimental methods to comprehensively characterize, and for the first time, the pharmacology of the M324 molecule. The first author of the work, Huabin Hu, has made an exhaustive prediction of the differential activity of the original drug and its product, which translates into different spectra of the phosphorylation pattern of cellular proteins. Carme Serra, from the MCS group at IQAC-CSIC, has synthesized the metabolite M324, which has allowed experimental verification of the computational prediction in biological and cellular assays. The results obtained could have implications for clinical treatment with Rucaparib and, in turn, open new opportunities for drug discovery.

In summary, the study points towards a new conceptual perspective in pharmacology: one that considers drug metabolism not as an undesirable process that degrades and eliminates the therapeutic molecule from the body, but rather as one that can have potential advantages from a therapeutic point of view. Indeed, the work highlights the importance of characterizing the activity of drug metabolites to comprehensively understand their clinical response and apply it in precision medicine.

The Bellvitge Biomedical Research Institute (IDIBELL) is a biomedical research center created in 2004. It is participated by the Bellvitge University Hospital and the Viladecans Hospital of the Catalan Institute of Health, the Catalan Institute of Oncology, the University of Barcelona and the City Council of L'Hospitalet de Llobregat.

IDIBELL is a member of the Campus of International Excellence of the University of Barcelona HUBc and is part of the CERCA institution of the Generalitat de Catalunya. In 2009 it became one of the first five Spanish research centers accredited as a health research institute by the Carlos III Health Institute. In addition, it is part of the "HR Excellence in Research" program of the European Union and is a member of EATRIS and REGIC. Since 2018, IDIBELL has been an Accredited Center of the AECC Scientific Foundation (FCAECC).

L'Hospitalet de Llobregat, February 8th, 2024. Once they enter the body, drugs, apart from carrying out their therapeutic function, are biochemically transformed by the action of the metabolic machinery, a process that facilitates their expulsion. This biotransformation results in a gradual disappearance of the drug, which is converted into its metabolites. These, in turn, can reach high concentrations in the body and also show a biological activity that may be different from that of the original drug. That is, the metabolites and the drug coexist in the body, and can cause effects different from those obtained with the individual molecules. This is the case of Rucaparib, a drug used in chemotherapy for ovarian cancer, breast cancer and, more recently, prostate cancer, and its metabolite, the M324 molecule. Rucaparib is part of a group of drugs designed to treat several types of cancers that show alterations in DNA repair. Specifically, they are inhibitors of the PARP1 enzyme, involved precisely in the process of repairing mutations in the genetic material.

A study led by researchers Albert A. Antolin, from the Oncobell program of the Bellvitge Biomedical Research Institute (IDIBELL) and ProCure of the Catalan Institute of Oncology (ICO), and Amadeu Llebaria, from the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC ), has shown that Rucaparib and its main metabolite M324 exhibit differential activities. Published in the journal Cell Chemical Biology, the paper has analyzed Rucaparib and M324, making a computational prediction of the metabolite's activity. The article describes the synthesis of M324 and its biological assay, demonstrating that the drug and its metabolite have differentiated activities and act synergistically in some prostate cancer cell lines. And that, surprisingly, M324 reduces the accumulation of the protein α-synuclein (an important component of Lewy bodies) in neurons derived from patients with Parkinson's, a neurodegenerative disease characterized by a movement disorder, and in which neurons do not produce sufficient amounts of the neurotransmitter dopamine.

Specifically, the synergy demonstrated between Rucaparib and M324 in prostate cancer cell lines could have an impact on clinical trials for advanced stages of this type of cancer. On the other hand, the fact that M324 is capable of reducing the abnormal accumulation of α-synuclein in neurons derived from stem cells of a Parkinson's patient, highlights the therapeutic potential of this metabolite and its possible pharmacological application for the treatment of this neurodegenerative disease. These results have been obtained thanks to the collaboration of the IDIBELL and ICO groups led by Miquel Àngel Pujana and Álvaro Aytés, and the group of Antonella Consiglio, from IDIBELL and the UB.

Researchers have used computational and experimental methods to comprehensively characterize, and for the first time, the pharmacology of the M324 molecule. The first author of the work, Huabin Hu, has made an exhaustive prediction of the differential activity of the original drug and its product, which translates into different spectra of the phosphorylation pattern of cellular proteins. Carme Serra, from the MCS group at IQAC-CSIC, has synthesized the metabolite M324, which has allowed experimental verification of the computational prediction in biological and cellular assays. The results obtained could have implications for clinical treatment with Rucaparib and, in turn, open new opportunities for drug discovery.

In summary, the study points towards a new conceptual perspective in pharmacology: one that considers drug metabolism not as an undesirable process that degrades and eliminates the therapeutic molecule from the body, but rather as one that can have potential advantages from a therapeutic point of view. Indeed, the work highlights the importance of characterizing the activity of drug metabolites to comprehensively understand their clinical response and apply it in precision medicine.

The Bellvitge Biomedical Research Institute (IDIBELL) is a biomedical research center created in 2004. It is participated by the Bellvitge University Hospital and the Viladecans Hospital of the Catalan Institute of Health, the Catalan Institute of Oncology, the University of Barcelona and the City Council of L'Hospitalet de Llobregat.

IDIBELL is a member of the Campus of International Excellence of the University of Barcelona HUBc and is part of the CERCA institution of the Generalitat de Catalunya. In 2009 it became one of the first five Spanish research centers accredited as a health research institute by the Carlos III Health Institute. In addition, it is part of the "HR Excellence in Research" program of the European Union and is a member of EATRIS and REGIC. Since 2018, IDIBELL has been an Accredited Center of the AECC Scientific Foundation (FCAECC).

END



ELSE PRESS RELEASES FROM THIS DATE:

Innovative coating prevents limescale formation

Innovative coating prevents limescale formation
2024-02-09
Hot water tanks, washing machines, kettles: limescale forms in every domestic appliance that comes into contact with (hot) water – especially in areas where the water is hard, meaning high in calcium. Often the only thing that helps is to use vinegar or a special descaler to dissolve the rock-​hard deposits and restore the appliance’s functionality. This is a nuisance in households – and an expensive problem in thermal power stations, for example those that generate electricity, where the formation of limescale is known as fouling. Heat exchangers are particularly prone to limescale, which greatly reduces the efficiency of the systems: ...

Novel technique has potential to transform breast cancer detection

Novel technique has potential to transform breast cancer detection
2024-02-09
OAK BROOK, Ill. – An innovative breast imaging technique provides high sensitivity for detecting cancer while significantly reducing the likelihood of false positive results, according to a study published today in Radiology: Imaging Cancer, a journal of the Radiological Society of North America (RSNA). Researchers said the technique has the potential to offer more reliable breast cancer screening for a broader range of patients. Mammography is an effective screening tool for early detection of breast cancer, but its sensitivity ...

Children's Hospital Colorado accepted as one of nine core sites nationally in the prestigious Pediatric Heart Network

2024-02-09
Children’s Hospital Colorado (Children’s Colorado) is announcing its recent acceptance into the Pediatric Heart Network (PHN), a collective of leading hospitals working to improve outcomes and quality of life for children – and more recently adults – with heart disease. The hospital’s Heart Institute will become one of nine clinical research centers across North America selected to be a part of this national network.  “We are thrilled to be accepted as a new core site for the Pediatric Heart Network,” said Shelley Miyamoto, MD, professor and Jack Cooper Millisor Chair of Pediatric Cardiology ...

New tumor spatial mapping tool will help clinicians assess aggressiveness of cancer and personalize treatment

2024-02-09
Scientists have developed a new AI tool that maps the function of proteins in a cancerous tumour, enabling clinicians to decide how to target treatment in a more precise way. In cancers such as clear cell renal cell carcinoma (ccRCC), responses to existing treatments are different for each patient, making it difficult to identify the right drug treatment regime for each patient. For example, cancer therapeutic Belzutifan has recently been approved to treat ccRCC, but only has a response rate of 49% in patients with the most common form of the condition. To understand better why some patients respond better than others, researchers from the Universities of Bath and Nottingham studied ...

Certain older Americans show hesitation around brain scan research

2024-02-09
Asian Americans are less likely than their white peers to participate in health research involving MRIs and addressing this hesitancy could improve research, according to a Rutgers Health-led study. Findings by the researchers, published in Alzheimer's & Dementia: Translational Research & Clinical Interventions, a journal of the Alzheimer’s Association, surveyed older adults about their experiences and perceptions of MRI brain imaging scans, their desire to learn results of scans and their attitudes related to dementia and overall research participation. According to the study, South Asian older adults – those 65 and older – are less likely than older white adults ...

Migration solves exoplanet puzzle

Migration solves exoplanet puzzle
2024-02-09
Ordinarily, planets in evolved planetary systems, such as the Solar System, follow stable orbits around their central star. However, many indications suggest that some planets might depart from their birthplaces during their early evolution by migrating inward or outward. This planetary migration might also explain an observation that has puzzled researchers for several years: the relatively low number of exoplanets with sizes about twice as large as Earth, known as the radius valley or gap. Conversely, there are many exoplanets smaller and larger than this size. “Six years ago, a reanalysis of data from the Kepler space telescope revealed a shortage of exoplanets with sizes around ...

New adhesive tape picks up and sticks down 2D materials as easily as child’s play

New adhesive tape picks up and sticks down 2D materials as easily as child’s play
2024-02-09
Fukuoka, Japan – Materials just atoms in thickness, known as two-dimensional (2D) materials, are set to revolutionize future technology, including in the electronics industry. However, commercialization of devices that contain 2D materials has faced challenges due to the difficulty in transferring these extremely thin materials from where they are made onto the device. Now, a research team from Kyushu University, in collaboration with Japanese company Nitto Denko, have developed a tape that can be used to stick 2D materials to many different surfaces, in an ...

Researchers discover cosmic dust storms from Type Ia supernova

2024-02-09
Cosmic dust—like dust on Earth—comprises groupings of molecules that have condensed and stuck together in a grain. But the exact nature of dust creation in the universe has long been a mystery. Now, however, an international team of astronomers from China, the United States, Chile, the United Kingdom, Spain, etc., has made a significant discovery by identifying a previously unknown source of dust in the universe: a Type Ia supernova interacting with gas from its surroundings.   The study was published in Nature Astronomy on Feb. 9, and was led by Prof. WANG Lingzhi from the South America Center for Astronomy of the Chinese Academy ...

New fossil site of worldwide importance uncovered in southern France

New fossil site of worldwide importance uncovered in southern France
2024-02-09
Nearly 400 exceptionally well-preserved fossils dating back 470 million years have been discovered in the south of France by two amateur paleontologists. This new fossil site of worldwide importance has been analyzed by scientists from the University of Lausanne, in collaboration with the CNRS and international teams. This discovery provides unprecedented information on the polar ecosystems of the Ordovician period. Paleontology enthusiasts have unearthed one of the world's richest and most diverse fossil sites from the Lower Ordovician period (around 470 million ...

Global study: Wild megafauna shape ecosystem properties

Global study: Wild megafauna shape ecosystem properties
2024-02-09
For millions of years, a variety of large herbivores, or megafauna, influenced terrestrial ecosystems. Among many others, these included elephants in Europe, giant wombats in Australia, and ground sloths in South America. However, these animals experienced a wave of extinctions coinciding with the worldwide expansion of humans, leading to dramatic but still not fully understood changes in ecosystems. Even the survivors of these extinctions strongly declined, and many are currently threatened with extinction.   While there are many case studies as well as theories about the effects of large animals, formal attempts to quantitatively synthesize their effects and establish ...

LAST 30 PRESS RELEASES:

DNA aptamer drug sensors can instantly detect cocaine, heroin and fentanyl – even when combined with other drugs

New project will use next-gen at-home rapid test to track COVID-19, RSV, and flu

SRI relaunches the PARC Forum event series as it celebrates the first anniversary of acquiring the storied Palo Alto Research Center

An inside look at Beech tree disease

New AI model draws treasure maps to diagnose disease

Breastfeeding after COVID-19 booster can give babies antibodies

Researchers closing in on genetic treatments for hereditary lung disease, vision loss

COVID-19 associated with increased risk for autoimmune inflammatory rheumatic diseases up to a year after infection

UC Irvine receives $15 million NSF grant for integrative movement research

University of Houston engineer Metin Akay featured in study highlighting 50 scientists' contributions to biomedical engineering advancements

JWST captures the end of planet formation

Good news—MS drugs taken while breastfeeding may not affect child development

Programs intended to reduce health insurance premiums may make coverage less affordable for the middle class

PrEP discontinuation in a US national cohort of sexual and gender minority populations, 2017–22

USC Study: Medicare Part D plans increased restrictions on drug coverage

Sacituzumab govitecan plus platinum-based chemotherapy in breast, bladder, and lung carcinomas

Global study unveils "problematic" use of porn

Newly discovered protein prevents DNA triplication

Less ice in the arctic ocean has complex effects on marine ecosystems and ocean productivity

Antarctica’s coasts are becoming less icy

New research shows migrating animals learn by experience

Modeling the origins of life: New evidence for an “RNA World”

Scientists put forth a smarter way to protect a smarter grid

An evolutionary mystery 125 million years in the making

Data science approach to identifying thermal conductivity-related structural factors in amorphous materials

Deciphering the male breast cancer genome

Detection of suicide-related emergencies among children using real-world clinical data: A free webinar from the Brain & Behavior Research Foundation

Editor-in-Chief of Sustainability and Climate Change Madhavi Venkatesan named USA TODAY Woman of the Year for Massachusetts for leading plastic bottle ban efforts

Tests show high-temperature superconducting magnets are ready for fusion

Zika vaccine safe, effective when administered during pregnancy

[Press-News.org] An anticancer drug opens a new path for the treatment of Parkinson's
The metabolic product of an anticancer drug demonstrates potential activity in neurons derived from Parkinson's patients and a synergistic action, together with the original drug, in prostate cancer cells